Iterum Therapeutics to Present Data at IDWeek 2025 Conference

Iterum Therapeutics will present data at IDWeek 2025, including two posters on risk factors for treatment failure in uUTIs and the in vitro activity of sulopenem against U.S. Enterobacterales clinical isolates. The company will also conduct a Learning Lounge on Tuesday, October 21, 2025, focusing on oral sulopenem.

Iterum Therapeutics plc, a company focused on delivering next-generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens, will present data at the Infectious Disease Society of America’s IDWeek 2025 conference in Atlanta, GA, from October 19-22, 2025. The company will present two posters and conduct a Learning Lounge on urinary tract infections in adult women.

The first poster, titled "Risk factors for treatment failure in patients with uncomplicated urinary tract infection," will be presented by Steven I. Aronin, MD, on Monday, October 20, 2025, from 12:15 p.m. to 1:30 p.m. in Poster Hall B4-5. The second poster, "In vitro activity of sulopenem and comparator agents against U.S. Enterobacterales clinical isolates, SENTRY antimicrobial surveillance program, 2023," will also be presented by Steven I. Aronin, MD, on Tuesday, October 21, 2025, from 12:15 p.m. to 1:30 p.m. in the same location. These posters will be available on the company’s website after the conference.

Additionally, Iterum Therapeutics will conduct a Learning Lounge on Tuesday, October 21, 2025, at 1:15 p.m. EST, focusing on "An Overview of Urinary Tract Infection in Adult Women: Focus on Oral Sulopenem." The presenters will be Steven I. Aronin, MD, and Michael Dunne, MD.

Iterum Therapeutics is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug-resistant pathogens. The company is advancing the development of sulopenem, a novel penem anti-infective compound, with both oral and IV formulations. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics. The company has received U.S. Food and Drug Administration (FDA) approval for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options. ORLYNVAH™ is commercially available in the United States. Iterum has also been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.